SAFC Pharma

SAFC Pharma Augments Assay Development Capabilities

SAFC Pharma Augments Assay Development Capabilities

From: SAFC-Global

  • 393
  • 0
  • 02 / 11 / 2009

SAFC Pharma™ - High-Potent API Manufacturing Through Fermentation Technology

Combining its exceptional expertise in small molecule chemistry, biologics and high-potent compound handling, SAFC Pharma offers unique large-scale fermentation-based high-potent API manu...

From: SAFC-Global

  • 1,400
  • 0
  • 02 / 12 / 2009

SAFC Pharma - Jerusalem - Fermentation Derived High-Potent APIs

SAFC PharmaTM has invested in a new HPAPI contract manufacturing fermentation facility in Jerusalem, Israel. The 50,000 sq. ft. state-of-the-art Biosafety Level 2 facility has been design...

From: SAFC-Global

  • 701
  • 0
  • 02 / 12 / 2009

SAFC Pharma - Conjugation Ad

As your complete pipeline partner, SAFC Pharma™ combines over 25 years of small molecule, biologics and high potency expertise to offer you the latest technologies available in oncology d...

From: SAFC-Global

  • 243
  • 0
  • 02 / 12 / 2009

SAFC Pharma - Targeted Drug Delivery Through Bio-Conjugation

As an industry leader in the conjugation of biological molecules with high potency APIs (HPAPIs), SAFC Pharma™ is among a handful of companies that can carry out the complexities of conj...

From: SAFC-Global

  • 1,014
  • 0
  • 02 / 12 / 2009

SAFC Pharma - High-Potent APIs and Cytotoxics

SAFC Pharma’s™ leading position in the fast-growing High-Potency Active Pharmaceutical Ingredients (HPAPI) market includes conjugation of HPAPIs to antibodies for exciting new anti-cancer...

From: SAFC-Global

  • 1,056
  • 0
  • 02 / 12 / 2009

SAFC Pharma - Viral Vaccines & Therapeutics

With over a decade of experience in manufacturing viral vectors and vaccines, SAFC Pharma™ has industry-leading expertise in this complex emerging technology. From process development to ...

From: SAFC-Global

  • 665
  • 0
  • 02 / 12 / 2009

SAFC Pharma - Complex Technolog Ad

As your complete pipeline partner, SAFC Pharma™ meets all your emerging technologies requirements no matter how complex your project.

From: SAFC-Global

  • 361
  • 0
  • 02 / 12 / 2009

SAFC Pharma - Fermentation Technology

Combining its exceptional expertise in small molecule chemistry, biologics and high-potent compound handling, SAFC Pharma offers unique large-scale fermentation-based high-potent API manu...

From: SAFC-Global

  • 1,357
  • 0
  • 02 / 12 / 2009

SAFC Pharma - Carlsbad - cGMP Viral Product Development and Manufacturing

SAFC Pharma’s Carlsbad, California (USA) operations specialize in the clinical manufacturing of intermediates and final products used in viral vaccines and gene therapies.

From: SAFC-Global

  • 616
  • 0
  • 02 / 12 / 2009

SAFC Pharma - St. Louis - Biologic APIs and Conjugation

SAFC Pharma’s St. Louis, Missouri (USA) campus is a key center of manufacturing excellence in cGMP biologics, with over 25 years experience in plant- and animal-based therapeutic protein ...

From: SAFC-Global

  • 612
  • 0
  • 02 / 12 / 2009

SAFC Pharma - API Ad

As a world-class integrated provider of API services for the global pharmaceutical market, SAFC Pharma™ can support your pipeline – all the way from development through commercialization.

From: SAFC-Global

  • 378
  • 0
  • 02 / 12 / 2009

SAFC Pharma - High Potency Ad

With more than 15 years experience in High-Potent APIs (HPAPIs) and cytotoxics manufacturing, SAFC Pharma™ is leading the industry to support this complex technology in oncology drug d...

From: SAFC-Global

  • 259
  • 0
  • 02 / 12 / 2009

SAFC Pharma - Madison - High-Potent API Manufacturing Experts

Through its site in Madison, Wisconsin (USA), SAFC Pharma is the industry leader in high-potent API manufacturing. This flagship Safebridge® certified manufacturing site features the high...

From: SAFC-Global

  • 1,010
  • 0
  • 02 / 12 / 2009

SAFC Pharma - Buchs Facility - cGMP API Manufacturing

SAFC Pharma’s Buchs, Switzerland facility specializes in complex, multi-step, organic custom synthesis of pre-registered APIs and key intermediates from Phase I to Phase III clinical tria...

From: SAFC-Global

  • 876
  • 0
  • 02 / 12 / 2009
1 2